FrancophonIA/ELRC3.0 huggingface dataset:
English: Capecitabine and its metabolites are predominantly excreted in urine; 95.5% of administered capecitabine dose is recovered in urine.
Danish: 95,5 % af den indgivne capecitabindosis genfandtes i urinen.
English: In patients with mild renal impairment (creatinine clearance 51-80 ml/min at baseline) no adjustment of the starting dose is recommended.
Danish: Til patienter med moderat nedsat nyrefunktion ved baseline er det for en initialdosis på 1.000 mg/m2 ikke nødvendigt med dosisjustering.Til patienter med let nedsat nyrefunktion (creatininclearance 5180 ml/min ved baseline) er dosisjustering ikke nødvendig.
English: Ecansya 300 mg film-coated tablets (tablets) are white to off white, oblong shaped, biconvex tablets of 14.6 mm in length and 6.7 mm in width, debossed with "300" on one side and plain on other side.
Danish: Ecansya 300 mg filmovertrukne tabletter (tabletter) er hvide til off-white, aflange, bikonvekse tabletter, 14,6 mm lange og 6,7 mm brede, præget med "300" på den ene side og jævne på den anden side.
English: - Ecansya 500 mg film-coated tablets Hypromellose (6cps)
Danish: - Ecansya 500 mg filmovertrukne tabletter Hypromellose (6cps)
English: MARKETING AUTHORISATION HOLDER KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Danish: INDEHAVER AF MARKEDSFØRINGSTILLADELSEN KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenien
English: Marketing Authorisation Holder KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenia
Danish: Indehaver af markedsføringstilladelsen KRKA, d.d., Novo mesto, Šmarješka cesta 6, 8501 Novo mesto, Slovenien
English: OTHER SPECIAL WARNING (S), IF NECESSARY
Danish: EVENTUELLE ANDRE SÆRLIGE ADVARSLER
English: Dose modifications for toxicity when capecitabine is used as a 3 weekly cycle in combination with other medicinal products should be made according to table 3 above for capecitabine and according to the appropriate summary of product characteristics for the other medicinal product(s).
Danish: Når capecitabin anvendes i tre ugers serie i kombination med andre lægemidler, skal dosisændring foretages i henhold til tabel 3 ovenfor for capecitabin og efter det pågældende produktresumé for det andet lægemiddel/de andre lægemidler.
English: • Grade 3 -1st appearance
Danish: • Grad 3 ved 1. forekomst
English: Ecansya 500 mg film-coated tablets (tablets) are peach coloured, oblong shaped, biconvex tablets of 15.9 mm in length and 8.4 mm in width, debossed with "500" on one side and plain on other side.
Danish: Ecansya 500 mg filmovertrukne tabletter (tabletter) er ferskenfarvede, aflange, bikonvekse tabletter, 15,9 mm lange og 8,4 mm brede, præget med "500" på den ene side og jævne på den anden side.
English: Neutropenia
Danish: Muskelsvaghed
English: Leucovorin 200 mg/m2
Danish: 600 mg/ m2
English: The tablets are white to off white, oblong shaped, biconvex tablets of 14.6 mm in length and 6.7 mm in width, debossed with "300" on one side and plain on other side.
Danish: Tabletterne er hvide til off-white, aflange, bikonvekse tabletter, 14,6 mm lange og 6,7 mm brede, præget med "300" på den ene side og jævne på den anden side.
English: For combination with irinotecan, the recommended starting dose is 800 mg/m2 when administered twice daily for 14 days followed by a 7-day rest period combined with irinotecan 200 mg/m2 on day 1.
Danish: Ved kombination med irinotecan er den anbefalede initialdosis 800 mg/m2, når det administreres to gange dagligt i 14 dage efterfulgt af en pause på 7 dage kombineret med irinotecan 200 mg/m2 på dag 1.Inklusionen af bevacizumab i et kombinationsregime har ingen indflydelse på initialdosis af capecitabin.
English: By reporting side effects you can help provide more information on the safety of this medicine.
Danish: Du eller dine pårørende kan også indberette bivirkninger direkte til Lægemiddelstyrelsen via det nationale rapporteringssystem anført i Appendiks V. Ved at indrapportere bivirkninger kan du hjælpe med at fremskaffe mere information om sikkerheden af dette lægemiddel.
English: 120 Patients were randomised to a modified XELIRI regimen with capecitabine 800 mg/m2 twice daily for two weeks followed by a 7-day rest period), irinotecan (200 mg/m2 as a 30 minute infusion on day 1 every 3 weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks); 127 patients were randomised to treatment with capecitabine (1000 mg/m2 twice daily for two weeks followed by a 7-day rest period), oxaliplatin (130 mg/m2 as a 2 hour infusion on day 1 every 3 weeks), and bevacizumab (7.5 mg/kg as a 30 to 90 minute infusion on day 1 every 3 weeks).
Danish: 120 patienter blev randomiseret til at få et modficeret XELIRI-regime med capecitabin (800 mg/m2 2 gange dagligt i to uger efterfulgt af 7 dages pause), irinotecan (200 mg/m2 som infusion over 30 minutter på dag 1 hver tredje uge) og bevacizumab (7,5 mg/kg som infusion over 30 til 90 minutter på dag 1 hver tredje uge).
English: Combination therapy with capecitabine and docetaxel in locally advanced or metastatic breast cancer Data from one multicentre, randomised, controlled phase III clinical trial support the use of capecitabine in combination with docetaxel for treatment of patients with locally advanced or metastatic breast cancer after failure of cytotoxic chemotherapy, including an anthracycline.
Danish: Data fra et randomiseret, kontrolleret, klinisk fase III-multicenterstudie støtter anvendelsen af capecitabin i kombination med docetaxel til behandling af patienter med lokal fremskreden eller metastatisk brystkræft hos hvem cytotoksisk kemoterapi, inklusive et antracyklin, har svigtet.
English: Combination therapy
Danish: Kombinationsbehandling
English: Mucosal inflammation, Pain in limb, Pain, Chills, Chest pain, Influenza-like illness,
Danish: Mukosal inflammation, Smerter i ekstremiteterne, Smerter, Kuldegysninger, Brystsmerter,
English: It may harm them,
Danish: Ødem,
English: Tablet core
Danish: Tabletkernen
English: ADRs are added to the appropriate frequency grouping (Very common or Common) according to the highest incidence seen in any of the major clinical trials and are only added when they were seen in addition to those seen with capecitabine monotherapy or seen at a higher frequency grouping compared to capecitabine monotherapy (see table 4).
Danish: Bivirkningerne er anført i en passende frekvensgruppering (Meget almindelig eller Almindelig) i henhold til den højeste hyppighed, der er set i et af de store kliniske studier.
English: Hypromellose (6cps), titanium dioxide (E171), talc.
Danish: Ecansya 300 mg filmovertrukne tabletter Hypromellose (6cps), titandioxid (E171), talkum.
English: The tablets are light peach colored, oblong shaped, biconvex tablets of 11.4 mm in length and 5.3 mm in width, debossed with "150" on one side and plain on other side.
Danish: Tabletterne er lyse ferskenfarvede, aflange, bikonvekse tabletter, 11,4 mm lange og 5,3 mm brede, præget med "150" på den ene side og jævne på den anden side.
English: Common side-effects (may affect up to 1 in 10 people) include: - decrease in blood sodium, magnesium or calcium, increase in blood sugar - nerve pain - ringing or buzzing in the ears (tinnitus), loss of hearing - vein inflammation - hiccups, change in voice - pain or altered/abnormal sensation in the mouth, pain in the jaw - sweating, night sweats - muscle spasm
Danish: Almindelige bivirkninger (kan påvirke op til 1 ud af 10 personer): - nedsat indhold af natrium, magnesium og kalk i blodet, stigning i blodsukker, - nervesmerter, - ringen eller summen i ørerne (tinnitus), høretab, - betændelse i venerne,
English: Combination treatment consisted of first-line capecitabine (1000 mg/m 2 twice daily for 14 days) combined with irinotecan (250 mg /m 2 on day 1) (XELIRI) and second-line capecitabine (1000 mg/m2 twice daily for 14 days) plus oxaliplatin (130 mg/m2 on day 1).
Danish: Den sekventielle behandling bestod af 1. linjebehandling med capecitabin (1.250 mg/m2 to gange daglig i 14 dage), 2. linjebehandling med irinotecan (350 mg/m 2 på dag 1) og 3. linjebehandling en kombination af capecitabin (1.000 mg/m 2 2 gange dagligt i 14 dage) med oxaliplatin (130 mg/m 2 på dag 1).
English: Hypromellose (6cps), titanium dioxide (E171), yellow iron oxide, red iron oxide (E172), talc.
Danish: Ecansya 500 mg filmovertrukne tabletter Hypromellose (6cps), titandioxid (E171), gul og rød jernoxid (E172), talkum.
English: Dihydropyrimidine dehydrogenase (DPD) activity is the rate limiting step.
Danish: Dihydropyrimidindehydrogenase (DPD) aktiviteten er det hastighedsbestemmende trin. DPD deficit kan medføre øget toksicitet af capecitabin (se pkt.
English: If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.
Danish: Kontakt lægen, før du tager dette lægemiddel, hvis lægen har fortalt dig, at du ikke tåler visse sukkerarter.
English: Neutropenia, Leucopenia,
Danish: Hovedpine, Sløvhed,
English: For Arm B, the XELIRI regimen used capecitabine 1000 mg/m twice daily for 14 days + irinotecan 250 mg/m2 on day 1.
Danish: I arm-B bestod det anvendte XELIRI-regime af 1.000 mg/m2 capecitabin 2 gange dagligt i 14 dage plus 250
English: Hepatobiliary disorders
Danish: Thromboflebitis
English: Aphasia, Memory impairment, Ataxia, Syncope, Balance disorder, Sensory disorder, Neuropathy peripheral
Danish: Synkope, Balanceforstyrrelser, Føleforstyrrelser, Perifer neuropati
English: The hazard ratio for overall survival was 0.94 (95% CI: 0.89; 1.00, p=0.0489) indicating that capecitabine-containing regimens are non-inferior to 5-FU-containing regimens.
Danish: Hazard ratio for samlet overlevelse var 0,94 (95 % konfidensinterval: 0,89; 1,00: p = 0,0489).
English: Herpes viral infection, Nasopharyngitis, Lower respiratory tract infection
Danish: Nasofaryngitis, Infektion i de nedre luftveje
English: The tablets are peach colored, oblong shaped, biconvex tablets of 15.9 mm in length and 8.4 mm in width, debossed with "500" on one side and plain on other side.
Danish: Tabletterne er ferskenfarvede, aflange, bikonvekse tabletter, 15,9 mm lange og 8,4 mm brede, præget med "500" på den ene side og jævne på den anden side.
English: Ecansya 500 mg tablets capecitabine
Danish: Ecansya 500 mg tabletter capecitabin
English: Ecansya 300 mg tablets capecitabine
Danish: Ecansya 300 mg tabletter capecitabin
English: Ecansya 150 mg tablets capecitabine
Danish: Ecansya 150 mg tabletter capecitabin
English: +Anaemia, Neutropenic fever, Thrombocytopenia
Danish: Blod og lymfesystem +Neutropeni, Leukopeni, Anæmi, Neutropenisk feber, Trombocytopeni
English: Starting Dose
Danish: Startdosis
English: heartburn (reflux of food from the stomach), blood in the stool - jaundice (yellowing of skin and eyes) - skin ulcer and blister, reaction of the skin with sunlight, reddening of palms, swelling or pain of the face - joint swelling or stiffness, bone pain, muscle weakness or stiffness - fluid collection in the kidneys, increased frequency of urination during the night, incontinence,
Danish: blod i afføringen - gulsot (gulfarvning af hud og øje) - sår og vabler på huden, solfølsom hud, rødme i håndfladerne, hævelse eller smerter i ansigtet, - hævede og/eller stive led, knoglesmerter, muskelsvaghed eller -stivhed - væskeansamling i nyrerne, øget vandladning om natten, inkontinens, blod i urinen, stigning i kreatinin i blodet (tegn på nedsat nyrefunktion) - unormal blødning fra skeden - hævelse, kulderystelser og stivhed
English: fainting, nerve damage (neuropathy) and problems with sensation - blurred or double vision - vertigo, ear pain - irregular heartbeat and palpitations (arrhythmias), chest pain and heart attack (infarction), - blood clots in the deep veins, high or low blood pressure, hot flushes, cold limbs (extremities),
Danish: nerveskader (neuropati) og føleforstyrrelser - sløret syn eller dobbeltsyn - svimmelhed, øresmerter - uregelmæssige hjerteslag (arytmi), og hjertebanken brystsmerter og hjertetilfælde (blodprop) - blodprop i de dybe vener, højt eller lavt blodtryk, hedeture, kolde hænder og fødder, lilla mærker på huden - blodprop i lungerne, sammenklappede lunger, ophostning af blod, astma, stakåndethed ved anstrengelse - forstoppelse, væskeansamling i maven, betændelse i tynd- og tyktarm, maven eller spiserøret,
English: - History of severe and unexpected reactions to fluoropyrimidine therapy, - Hypersensitivity to capecitabine or to any of the excipients listed in section 6.1 or fluorouracil, - In patients with known complete absence of dihydropyrimidine dehydrogenase (DPD) activity
Danish: - Tidligere alvorlige og uventede reaktioner på behandling med fluorpyrimidin, - Overfølsomhed over for det aktive stof eller over for et eller flere af hjælpestofferne anført i pkt.
English: In this trial, 944 patients were randomised to 3-week cycles for 24 weeks with capecitabine (1000 mg/m2 twice daily for 2 weeks followed by a 1-week rest period) in combination with oxaliplatin (130 mg/m2 intravenous infusion over 2-hours on day 1 every 3 weeks); 942 patients were randomised to bolus 5-FU and leucovorin.
Danish: I dette studie blev 944 patienter randomiseret til 3-ugers-cykler i 24 uger med capecitabin (1.000 mg/m2 to gange dagligt i 2 uger, efterfulgt af én uges pause) i kombination med oxaliplatin (130 mg/m2 intravenøs infusion over 2 timer på dag 1 hver 3. uge).
English: Neoplasm benign, malignant and unspecified
Danish: Benigne, maligne og uspecificerede tumorer (inkl.cyster og polypper)
English: Sore throat, Dysaesthesia pharynx
Danish: Ondt i halsen, Farynxdysæstesi
English: - sleeplessness (insomnia), depression - headache, sleepiness, dizziness, abnormal sensation in the skin (numbness or tingling sensation), taste changes - eye irritation, increased tears, eye redness (conjunctivitis) - inflammation of the veins (thrombophlebitis) - shortness of breath, nose bleeds, cough, runny nose - cold sores or other herpes infections - infections of the lungs or respiratory system (e.g. pneumonia or bronchitis) - bleeding from the gut, constipation, pain in upper abdomen, indigestion, excess wind, dry mouth - skin rash, hair loss (alopecia), skin reddening, dry skin, itching (pruritus), skin discolouration,
Danish: Almindelige bivirkninger (kan påvirke op til 1 ud af 10 personer): - nedsat antal hvide og røde blodlegemer (kan ses i blodprøver) - væskemangel, vægttab - søvnløshed, depression - hovedpine, søvnighed, svimmelhed, abnorm følelse i huden (følelsesløshed eller prikken og stikken), ændret smagssans - irriterede øjne, tåreflåd, røde øjne (øjenbetændelse ) - betændelse i venerne (tromboflebitis) - stakåndethed, næseblødning, hoste, løbende næse - forkølelsessår eller andet herpesudbrud - betændelse i lunger eller luftveje (fx lungebetændelse eller bronkitis) - blødning fra tarmen, forstoppelse, smerter i den øverste del af maven, fordøjelsesproblemer, luft i maven, tør mund - udslæt, hårtab (alopeci), hudrødme , tør hud, kløe, misfarvet hud, hudafskalning , betændelse i huden, negleproblemer - ledsmerter, smerter i arme, ben, bryst eller ryg - feber, hævede arme og ben, sygdomsfølelse - leverproblemer (kan ses i blodprøver) og stigning af bilirubin i blodet (udskilles gennem leveren)
English: The primary efficacy analyses in the per protocol population demonstrated non-inferiority in overall survival for capecitabine- vs 5-FU-based regimens (hazard ratio 0.86; 95% CI 0.8 - 0.99) and for oxaliplatin- vs cisplatin-based regimens (hazard ratio 0.92; 95% CI 0.80 - 1.1).
Danish: Den primære effektanalyse i per protokolpopulationen demonstrerede non-inferioritet i samlet overlevelse for capecitabin versus 5-FU regimerne (hazard ratio 0,86; 95 %konfidensinterval 0,8
English: A significant reduction in the risk of progression was associated with FOLFIRI (HR, 0.76; 95%CI, 0.62-0.95; P <0.01), a result partly due to poor tolerance to the XELIRI regimens used.
Danish: FOLFIRI blev associeret med en signifikant reduktion i risikoen for progression (hazard ratio = 0,76; 95 % konfidensinterval 0,62-0,95; p < 0,01).
English: Hepatic impairment due to liver metastases.
Danish: Leverinsufficiens pga. Levermetastaser.
English: Cardiotoxicity (see section 4.4):
Danish: Kardiotoksicitet (se pkt.
English: Dose modifications applied should be applied for the precipitating adverse event as necessary (see section 4.2).
Danish: Dosis ændres i henhold til de ovenfor anførte retningslinjer for den udløsende bivirkning (se pkt.
English: - EOX: epirubicin (50 mg/m 2 as a bolus on day 1 every 3 weeks), oxaliplatin (130 mg/m 2 given as a 2 hour infusion on day 1 every three weeks), and capecitabine (625 mg/m 2 twice daily continuously).
Danish: - EOX: epirubicin (50 mg/ m 2 som bolus på dag 1 hver 3. uge), oxaliplatin (130 mg/m 2 som en to-timers infusion på dag 1 hver 3. uge) og capecitabin (625 mg/m 2 to gange dagligt givet kontinuerligt).
English: The median follow up at the time of the primary analyses in the intent-to-treat population was 2.1 years; data from analyses following an additional 6 months of follow up are also included in table 9.
Danish: Data fra analyser efter yderligere 6 måneders follow-up fremgår også af tabel 9.
English: Contusion
Danish: Antacida
English: NAME OF THE MEDICINAL PRODUCT Ecansya 150 mg film-coated tablets multilingual blister:
Danish: LÆGEMIDLETS NAVN Ecansya 150 mg filmovertrukne tabletter flersprogede blisterkort:
English: Jaundice
Danish: Gulsot
English: - ECF: epirubicin (50 mg/ m2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m2 as a two hour infusion on day 1 every 3 weeks) and 5-FU (200 mg/m2 daily given by continuous infusion via a central line).
Danish: - ECF: epirubicin (50 mg/ m2 som bolus på dag 1 hver 3. uge), cisplatin (60 mg/m2 som en to timers infusion på dag 1 hver 3. uge) og 5-FU (200 mg/m 2 dagligt givet som kontinuerlig infusion via et centralt venekateter).
English: As the potential for harm to the nursing infant is unknown, breast-feeding should be discontinued while receiving treatment with capecitabine and for 2 weeks after the final dose.
Danish: Der er fundet betragtelige koncentrationer af capecitabin og dets metabolitter i mælken hos diegivende musDa den potentielt skadelige virkning for det ammende spædbarn er ukendt, skal amning afbrydes under behandling med capecitabin og i 2 uger efter sidste dosis.
English: Data from two multicentre phase II clinical trials support the use of capecitabine monotherapy for treatment of patients after failure of taxanes and an anthracycline-containing chemotherapy regimen or for whom further anthracycline therapy is not indicated.
Danish: Monoterapi med capecitabin efter svigt af taxaner og kemoterapi, som indeholder antracykliner, og af patienter til hvem behandling med antracykliner ikke er indiceret Data fra to kliniske multicenterstudier i fase II støtter anvendelsen af capecitabin-monoterapi hos patienter, hos hvem taxoider og et antracyklinindeholdende kemoterapiregime har svigtet, eller hos hvem yderligere antracyklinbehandling ikke er indiceret.
English: - ECX: epirubicin (50 mg/m 2 as a bolus on day 1 every 3 weeks), cisplatin (60 mg/m 2 as a two hour infusion on day 1 every 3 weeks), and capecitabine (625 mg/m 2 twice daily continuously).
Danish: - ECX: epirubicin (50 mg/ m2 som bolus på dag 1 hver 3. uge), cisplatin (60 mg/m2 som en totimers infusion på dag 1 hver 3. uge) og capecitabin (625 mg/m2 to gange dagligt givet kontinuerligt).
English: Ecansya 500 mg film-coated tablets
Danish: Ecansya 500 mg filmovertrukne tabletter
English: Dyspnoea, Epistaxis, Cough, Rhinorrhoea
Danish: Dyspnø, Epistaxis, Hoste,
English: - EOF: epirubicin (50 mg/m 2 as a bolus on day 1 every 3 weeks), oxaliplatin (130 mg/m 2 given as a 2 hour infusion on day 1 every three weeks), and 5-FU (200 mg/m 2 daily given by continuous infusion via a central line).
Danish: - EOF: epirubicin (50 mg/ m2 som bolus på dag 1 hver 3. uge), oxaliplatin (130 mg/m2 som en totimers infusion på dag 1 hver 3. uge) og 5-FU (200 mg/m2 dagligt givet som kontinuerlig infusion via en central linje).
English: Ecansya 300 mg film-coated tablets
Danish: Ecansya 300 mg filmovertrukne tabletter
English: Median PFS and overall survival (OS) times were shorter for XELIRI versus FOLFIRI (PFS 5.9 versus 9.6 months and OS 14.8 versus 19.9 months), in addition to which excessive rates of diarrhoea were reported in patients receiving the XELIRI regimen (41% XELIRI, 5.1% FOLFIRI).
Danish: Den mediane progressionsfri overlevelse og samlede overlevelse var kortere for XELIRI versus FOLFIRI (progressionsfri overlevelse 5,9 måneder versus 9,6 måneder og samlet overlevelse 14,8 versus 19,9 måneder).
English: Vaginal haemorrhage
Danish: Vaginal blødning
English: NAME OF THE MEDICINAL PRODUCT Ecansya 300 mg film-coated tablets multilingual blister:
Danish: LÆGEMIDLETS NAVN Ecansya 300 mg filmovertrukne tabletter flersprogede blisterkort:
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 150 mg capecitabine.
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver filmovertrukken tablet indeholder 150 mg capecitabin.
English: General
Danish: Generelt
English: - In combination with docetaxel: an increased incidence of grade 3 or 4 treatment-related adverse reactions and treatment-related serious adverse reactions were observed in patients 60 years of age or more (see section 5.1).
Danish: behandlingsrelaterede bivirkninger og behandlingsrelaterede alvorlige bivirkninger hos patienter på 60 år og derover (se pkt.
English: Stevens-Johnson Syndrome and toxic Epidermal Necrolysis (very rare) (see section 4.4.)
Danish: Kutan lupus erythematosus (sjælden), Alvorlige hudreaktioner såsom StevensJohnsons syndrom og toksisk epidermal nekrolyse (meget sjælden) (se pkt.
English: NAME OF THE MEDICINAL PRODUCT Ecansya 500 mg film-coated tablets multilingual blister:
Danish: LÆGEMIDLETS NAVN Ecansya 500 mg filmovertrukne tabletter flersprogede blisterkort:
English: Ecansya 150 mg film-coated tablets
Danish: Ecansya 150 mg filmovertrukne tabletter
English: What Ecansya looks like and contents of the pack Ecansya 150 mg film-coated tablets (tablets) are light peach coloured, oblong shaped, biconvex tablets of 11.4 mm in length and 5.3 mm in width, debossed with "150" on one side and plain on other side.
Danish: Ecansya 150 mg filmovertrukne tabletter (tabletter) er lyse ferskenfarvede, aflange, bikonvekse tabletter, 11,4 mm lange og 5,3 mm brede, præget med "150" på den ene side og jævne på den anden side.
English: Neurotoxicity, Tremor, Neuralgia, Hypersensitivity reaction, Hypoaesthesia
Danish: Neurotoksicitet, Tremor, Neuralgi,
English: Thrombophlebitis Deep vein thrombosis, Hypertension,
Danish: Dyb venethrombose, Hypertension, Petekkier, Hypotension, Hedeture,
English: NAME OF THE MEDICINAL PRODUCT Ecansya 500 mg film-coated tablets capecitabine
Danish: LÆGEMIDLETS NAVN Ecansya 500 mg filmovertrukne tabletter capecitabin
English: NAME OF THE MEDICINAL PRODUCT Ecansya 150 mg film-coated tablets capecitabine
Danish: LÆGEMIDLETS NAVN Ecansya 150 mg filmovertrukne tabletter capecitabin
English: -2nd appearance -3rd appearance
Danish: ved 2. forekomst ved 3. forekomst
English: NAME OF THE MEDICINAL PRODUCT Ecansya 300 mg film-coated tablets capecitabine
Danish: LÆGEMIDLETS NAVN Ecansya 300 mg filmovertrukne tabletter capecitabin
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 500 mg capecitabine.
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver filmovertrukken tablet indeholder 500 mg capecitabin.
English: STATEMENT OF ACTIVE SUBSTANCE(S) Each film-coated tablet contains 300 mg capecitabine.
Danish: ANGIVELSE AF AKTIVT STOF/AKTIVE STOFFER Hver filmovertrukken tablet indeholder 300 mg capecitabin.
English: Data from a multicentre, randomised, controlled phase III clinical trial in patients with advanced gastric cancer supports the use of capecitabine for the first-line treatment of advanced gastric cancer
Danish: Data fra et randomiseret, kontrolleret, klinisk fase III-multicenterstudie hos patienter med fremskreden ventrikelkræft støtter anvendelsen af capecitabin som 1. linjebehandling af fremskreden ventrikelkræft (ML17032).
English: Fatigue, Asthenia
Danish: Træthed, Asteni